title: [Nephrotic syndrome due to metabolic disease--special reference to diabetic nephropathy].
abstract: Diabetes has become the most common single cause of end stage renal disease. Nephrotic syndrome is often manifested in the progression of diabetic nephropathy. Diabetic nephropathy has several pathways for development, such as glomerular hyperfiltration, upregulation of protein kinase C, advanced glycation end products, activation of polyol pathway, increased oxidative stress and upregulation of growth factors. Intensive control of blood pressure and the use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker can protect the progression of nephropathy with nephrotic syndrome. However further studies are necessary for the clinical guidline in patients with diabetic nephropathy manifesting with nephrotic syndrome.
authors.affiliation: Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry.
authors.forename: Sakiko
authors.initials: S
authors.lastname: Ohga
authors.forename: Kenichi
authors.initials: K
authors.lastname: Shikata
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Makino
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D018450:Disease Progression; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D018384:Oxidative Stress; D011108:Polymers / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D005343:Fibrinolytic Agents; D017127:Glycation End Products, Advanced; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D011108:Polymers; C024617:polyol; D011493:Protein Kinase C